NEW YORK (GenomeWeb News) – Vela Diagnostics today announced a deal with Thomas Jefferson University and Hospitals to jointly develop molecular diagnostics aimed at cancer and infectious diseases.

The Singapore-based company said the two partners are currently deciding on several projects, including developing next-generation- and PCR-based assays. Using new technologies, Thomas Jefferson will help VelaDx develop and validate the assays. VelaDx will seek regulatory approval for the assays on a global basis.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In PNAS this week: spatiotemporal study of lncRNA expression, role of extrachromosomal, circular DNAs in yeast, and more.

A European team has launched a four-year study to develop a test to gauge cervical, ovarian, uterine, or aggressive breast cancer risk in women.

As interest in personalized medicine grows, government contractors are entering the field, the Washington Post reports.

In PLOS this week: Plasmodium knowlesi population genetics, oral microbiome of infants and children, and more.